Książka to bogate kompendium na temat e-biznesu.Omawia kluczowe zagadnienia w jasny i zrozumiały sposób.Prowadzi nas przez różne elementy biznesu.Zawiera wiele wskazówek które mogą znacznie pomóc przedsiębiorcy
The document summarizes studies on using radioactive iodine-labeled lipiodol (131I lipiodol) as a neoadjuvant treatment for hepatocellular carcinoma (HCC) prior to liver resection or transplantation. It found that 131I lipiodol allowed resection of larger HCC tumors (>3cm) with 3-year survival of 42%. For liver transplantation, 131I lipiodol prior to the procedure led to 5-year survival of 77% for HCC of all sizes, compared to 18% without neoadjuvant treatment, and no patients who received 131I lipiodol experienced HCC recurrence.
This document discusses endoscopic therapies for the management of variceal hemorrhage, specifically endoscopic sclerotherapy (EST) and endoscopic variceal ligation (EVL). It provides background on variceal bleeding and survival rates over time. It then describes the modalities and techniques of EST and EVL, including injection methods, sclerosing agents used, risks, and indications. Randomized controlled trials comparing EST and EVL are summarized, showing higher eradication rates with EVL. In conclusion, endoscopic therapies like EST and EVL are effective for controlling acute variceal bleeding and reducing recurrence when used for primary or secondary prophylaxis.
1) The surgical treatment of portal hypertension has evolved significantly in Egypt over the last century, driven by changes in liver pathology and the development of new techniques.
2) Initially, procedures like splenectomy were used but caused only temporary effects. Total portosystemic shunts were then introduced but were later abandoned due to high mortality and morbidity rates.
3) More selective surgeries and techniques were developed like Hassab's operation and mesocaval shunts but still had issues. The distal splenorenal shunt became more widely used as a selective shunt.
This document discusses chemotherapy options for biliary tree carcinoma. It begins by outlining the increasing mortality rates and poor prognosis of the disease. It then provides detailed information on the anatomical classification, histological classification, definition, risk factors, and problems associated with diagnosis and treatment. The document discusses surgery as the only potentially curative option but notes that most patients present with advanced, unresectable disease. It reviews several palliative chemotherapy regimens and their response rates and survival benefits, with various gemcitabine-based combinations showing the most promise. The challenges of treating this rare cancer are also summarized.
This document discusses the multimodal treatment of hepatocellular carcinoma. It begins by noting that 70% of HCC occurs in patients with cirrhosis. Available treatment methods include surgical resection, liver transplantation, transarterial embolization, chemotherapy, and various ablation techniques. Surgical resection has improved and offers the best chance of cure for non-cirrhotic patients, though recurrence rates are high. Liver transplantation offers the best disease-free survival for selected cirrhotic patients meeting criteria such as tumor size and number, but organ shortage is a major limitation. Other treatments such as arterial embolization and chemotherapy have limited or debated efficacy.
This document summarizes a study comparing outcomes of surgical treatment for intrahepatic cholangiocarcinoma (ICC) and hilar cholangiocarcinoma (Klatskin tumor). 59 patients who underwent liver resection for these tumors were analyzed. Klatskin tumors required more extensive resections and had higher postoperative morbidity. 5-year survival was similar for both tumor types at around 35%. Expression of the p27 protein was associated with lower recurrence rates and better survival outcomes. Surgical resection remains the primary treatment when possible but molecular markers may help guide future adjuvant therapies.
The document discusses the proximal splenorenal shunt procedure for patients with liver cirrhosis and portal hypertension combined with hypersplenism. The procedure involves creating a shunt from the splenic vein to the left renal vein to decompress the portal system. It is indicated for select patients as an alternative to other procedures to prevent variceal bleeding while removing the spleen. However, it carries risks of hepatic encephalopathy, worsening liver function, and is not suitable for future transplantation. The authors' experience with 17 patients who underwent this procedure is presented, along with postoperative outcomes.
The document discusses various treatment options for portal hypertension and its complications. It covers surgical procedures like devascularization operations, portosystemic shunts and splenorenal shunts that are aimed at preventing bleeding, stopping active bleeding, and preventing recurrent variceal bleeding. The choice of surgical treatment depends on factors like the severity of bleeding, liver dysfunction, and type of portal hypertension.
The document discusses different surgical treatments for portal hypertension between 1877-2003. It lists various types of shunt procedures that were developed over time to reduce portal pressure, including Eck-Pavlov-Vidal shunt in 1967, Warren shunt in 1967, and Starzl auxiliary liver transplantation in 1973. The document also discusses surgical treatments for Budd-Chiari syndrome and ascites, such as portocaval shunts, mesenterico-caval shunts, and LeVeen shunts. It concludes by providing data on the types of shunt procedures performed between 1997-2003 for portal hypertension treatment and their results.
TIPSS is a procedure that creates a permanent connection between the portal and hepatic veins to reduce portal hypertension. It has several indications including uncontrolled variceal bleeding and refractory ascites. The procedure involves catheterization of the jugular vein and placement of a stent. Complications can include thrombosis, hemorrhage, and encephalopathy. Success rates are over 80% for variceal bleeding and 50% for ascites, but secondary dysfunction occurs in 40% after 1 year often requiring revision. TIPSS provides immediate reduction in portal pressure and is less invasive than surgical shunting.
The document discusses pathogenesis and management of portal hypertension. It covers hemodynamic assessment of portal hypertension, causes of non-cirrhotic portal hypertension including nodular regenerative hyperplasia. Animal models of portal hypertension are described. The role of nitric oxide and endothelin in regulating vascular tone is discussed. Clinical consequences of cirrhotic portal hypertension include variceal bleeding. Management of acute variceal bleeding involves vasoactive drugs and endoscopic therapy. Secondary prophylaxis to prevent rebleeding involves non-selective beta-blockers or band ligation.
The document discusses guidelines for evaluating and treating hepatic metastases from colorectal cancer. It recommends investigations like CT, MRI, and ultrasound to evaluate metastases. Metastases are considered immediately resectable if the surgery is technically possible and leaves at least 40% of liver volume. Resection may be possible but risky if it requires complex procedures. Factors like number, size and location of metastases impact prognosis but are not absolute contraindications to resection. Repeat resection of recurrent metastases can provide long-term survival.
This document summarizes various radiation therapy modalities for treating hepatic malignant tumors. It discusses external beam radiotherapy techniques like conventional radiotherapy, 3D conformal radiotherapy, stereotactic radiotherapy, and proton radiotherapy. It also covers internal radiotherapy techniques like selective internal radiotherapy using yttrium microspheres, metabolic radiotherapy with iodine-131 lipiodol, and brachytherapy. The document provides details on each technique's dosimetry, efficacy, and safety considerations.
1. The document discusses the history and mechanisms of radiofrequency ablation (RFA) for treating hepatic tumors. RFA uses alternating current within 200-1200 MHz to generate heat and coagulate tissue.
2. RFA can be performed percutaneously, laparoscopically, or during open surgery. Different ablation schemes and needle types are used depending on tumor size and location.
3. Complications of RFA include wound infection, bleeding, and abscesses. Studies show high rates of initial tumor necrosis but frequent recurrence within a year.
This document discusses the management of cholangiocarcinoma based on the author's experience at the Mansoura University Gastroenterology Surgical Center in Egypt. Some key points include:
- Cholangiocarcinoma is the second most common malignant liver tumor after hepatocellular carcinoma.
- Surgical resection remains the main treatment when possible but many cases are unresectable due to advanced stage at presentation.
- Of 385 patients treated between 1995-2002, 216 had central cholangiocarcinoma and most (79%) of these were unresectable.
- For unresectable cases, various palliative treatments were used with a mean survival of 5.8
The document discusses classification and surgical treatment options for extrahepatic bile duct cancer. It examines preoperative biliary drainage and portal embolization. Surgical techniques discussed include laparoscopy, posterior approach, tumor resection, hepatectomy, and caudate lobe resection. Operative procedures and mortality are analyzed according to tumor location, TNM classification, and staging. Long-term survival outcomes are presented for different patient groups and surgical approaches.
1) This document discusses liver surgery for hepatocellular carcinoma (HCC), with a focus on techniques and outcomes in Japan.
2) The use of intraoperative ultrasound during liver surgery has enabled more limited and precise resections, such as subsegmentectomies, while preserving important vascular structures.
3) Hepatic resection for HCC has become much safer over time, with mortality rates decreasing to less than 1% at specialized centers due to techniques like intermittent inflow occlusion and precise limited resections guided by intraoperative ultrasound.
This document discusses antiviral therapy peri-liver transplantation. It provides data on primary liver disease in adult transplant recipients, with chronic hepatitis C being the most common at 20.7-40%. It also shows survival rates after transplantation by diagnosis. Therapeutic strategies for patients with HBV, HDV, and HCV undergoing liver transplantation aim to prevent recurrent infection of the graft. Recurrence of HBV infection is related to liver disease and HBV replicative status pre-transplant. Combination therapy with hepatitis B immune globulin and antiviral drugs like lamivudine is most effective for preventing HBV recurrence post-transplant according to various studies cited. Guidelines are provided for HBV prophylaxis and treatment of recurrence after
This document discusses liver transplantation for hepatitis C virus (HCV) disease. It outlines that HCV reinfection is common after transplantation, occurring in 87-97% of cases. There are different patterns of HCV recurrence post-transplant, including minimal liver injury, chronic HCV, and cholestatic HCV. Factors associated with increased rates of fibrosis post-transplant include older recipient age, bolus steroid use for rejection, induction with mycophenolic acid, and short duration of prednisone use. High pre-transplant HCV RNA levels are also associated with worse patient and graft survival outcomes.
- Liver resection (LR) and liver transplantation (LTx) are two treatment options for hepatocellular carcinoma (HCC). This study compares outcomes of 282 patients receiving LR and 187 receiving LTx.
- Patients who received LTx had a higher perioperative mortality rate compared to LR patients (18.1% vs 4.5%), mainly due to sepsis, multiple organ failure, and vascular complications. Late mortality was higher in LR patients and mainly due to tumor recurrence.
- Recurrence rates were significantly higher after LR (47.4% vs 9%), and survival after recurrence was also lower with LR. Factors associated with recurrence and survival included tumor characteristics such as α-fetoprotein levels,
1. Antiviral therapy both before and after liver transplantation is important to prevent recurrent infection of the graft by hepatitis B and C viruses.
2. Combination therapy with hepatitis B immune globulin and antiviral drugs like lamivudine is effective at preventing HBV recurrence in most patients.
3. Recurrence of HCV infection after transplantation is very common, but antiviral treatment with interferon or pegylated interferon plus ribavirin can achieve sustained virologic response in some patients and prevent progression of liver disease.
This document summarizes a study comparing outcomes of surgical treatment for intrahepatic cholangiocarcinoma (ICC) and hilar cholangiocarcinoma (Klatskin tumor). 59 patients who underwent liver resection for these tumors were analyzed. Klatskin tumors required more extensive resections and had higher postoperative morbidity. 5-year survival was similar for both tumor types at around 35%. Expression of the p27 protein was associated with lower recurrence rates and better survival outcomes. Surgical resection remains the primary treatment when possible but molecular markers may help guide future adjuvant therapies.
The document discusses the proximal splenorenal shunt procedure for patients with liver cirrhosis and portal hypertension combined with hypersplenism. The procedure involves creating a shunt from the splenic vein to the left renal vein to decompress the portal system. It is indicated for select patients as an alternative to other procedures to prevent variceal bleeding while removing the spleen. However, it carries risks of hepatic encephalopathy, worsening liver function, and is not suitable for future transplantation. The authors' experience with 17 patients who underwent this procedure is presented, along with postoperative outcomes.
The document discusses various treatment options for portal hypertension and its complications. It covers surgical procedures like devascularization operations, portosystemic shunts and splenorenal shunts that are aimed at preventing bleeding, stopping active bleeding, and preventing recurrent variceal bleeding. The choice of surgical treatment depends on factors like the severity of bleeding, liver dysfunction, and type of portal hypertension.
The document discusses different surgical treatments for portal hypertension between 1877-2003. It lists various types of shunt procedures that were developed over time to reduce portal pressure, including Eck-Pavlov-Vidal shunt in 1967, Warren shunt in 1967, and Starzl auxiliary liver transplantation in 1973. The document also discusses surgical treatments for Budd-Chiari syndrome and ascites, such as portocaval shunts, mesenterico-caval shunts, and LeVeen shunts. It concludes by providing data on the types of shunt procedures performed between 1997-2003 for portal hypertension treatment and their results.
TIPSS is a procedure that creates a permanent connection between the portal and hepatic veins to reduce portal hypertension. It has several indications including uncontrolled variceal bleeding and refractory ascites. The procedure involves catheterization of the jugular vein and placement of a stent. Complications can include thrombosis, hemorrhage, and encephalopathy. Success rates are over 80% for variceal bleeding and 50% for ascites, but secondary dysfunction occurs in 40% after 1 year often requiring revision. TIPSS provides immediate reduction in portal pressure and is less invasive than surgical shunting.
The document discusses pathogenesis and management of portal hypertension. It covers hemodynamic assessment of portal hypertension, causes of non-cirrhotic portal hypertension including nodular regenerative hyperplasia. Animal models of portal hypertension are described. The role of nitric oxide and endothelin in regulating vascular tone is discussed. Clinical consequences of cirrhotic portal hypertension include variceal bleeding. Management of acute variceal bleeding involves vasoactive drugs and endoscopic therapy. Secondary prophylaxis to prevent rebleeding involves non-selective beta-blockers or band ligation.
The document discusses guidelines for evaluating and treating hepatic metastases from colorectal cancer. It recommends investigations like CT, MRI, and ultrasound to evaluate metastases. Metastases are considered immediately resectable if the surgery is technically possible and leaves at least 40% of liver volume. Resection may be possible but risky if it requires complex procedures. Factors like number, size and location of metastases impact prognosis but are not absolute contraindications to resection. Repeat resection of recurrent metastases can provide long-term survival.
This document summarizes various radiation therapy modalities for treating hepatic malignant tumors. It discusses external beam radiotherapy techniques like conventional radiotherapy, 3D conformal radiotherapy, stereotactic radiotherapy, and proton radiotherapy. It also covers internal radiotherapy techniques like selective internal radiotherapy using yttrium microspheres, metabolic radiotherapy with iodine-131 lipiodol, and brachytherapy. The document provides details on each technique's dosimetry, efficacy, and safety considerations.
1. The document discusses the history and mechanisms of radiofrequency ablation (RFA) for treating hepatic tumors. RFA uses alternating current within 200-1200 MHz to generate heat and coagulate tissue.
2. RFA can be performed percutaneously, laparoscopically, or during open surgery. Different ablation schemes and needle types are used depending on tumor size and location.
3. Complications of RFA include wound infection, bleeding, and abscesses. Studies show high rates of initial tumor necrosis but frequent recurrence within a year.
This document discusses the management of cholangiocarcinoma based on the author's experience at the Mansoura University Gastroenterology Surgical Center in Egypt. Some key points include:
- Cholangiocarcinoma is the second most common malignant liver tumor after hepatocellular carcinoma.
- Surgical resection remains the main treatment when possible but many cases are unresectable due to advanced stage at presentation.
- Of 385 patients treated between 1995-2002, 216 had central cholangiocarcinoma and most (79%) of these were unresectable.
- For unresectable cases, various palliative treatments were used with a mean survival of 5.8
The document discusses classification and surgical treatment options for extrahepatic bile duct cancer. It examines preoperative biliary drainage and portal embolization. Surgical techniques discussed include laparoscopy, posterior approach, tumor resection, hepatectomy, and caudate lobe resection. Operative procedures and mortality are analyzed according to tumor location, TNM classification, and staging. Long-term survival outcomes are presented for different patient groups and surgical approaches.
1) This document discusses liver surgery for hepatocellular carcinoma (HCC), with a focus on techniques and outcomes in Japan.
2) The use of intraoperative ultrasound during liver surgery has enabled more limited and precise resections, such as subsegmentectomies, while preserving important vascular structures.
3) Hepatic resection for HCC has become much safer over time, with mortality rates decreasing to less than 1% at specialized centers due to techniques like intermittent inflow occlusion and precise limited resections guided by intraoperative ultrasound.
This document discusses antiviral therapy peri-liver transplantation. It provides data on primary liver disease in adult transplant recipients, with chronic hepatitis C being the most common at 20.7-40%. It also shows survival rates after transplantation by diagnosis. Therapeutic strategies for patients with HBV, HDV, and HCV undergoing liver transplantation aim to prevent recurrent infection of the graft. Recurrence of HBV infection is related to liver disease and HBV replicative status pre-transplant. Combination therapy with hepatitis B immune globulin and antiviral drugs like lamivudine is most effective for preventing HBV recurrence post-transplant according to various studies cited. Guidelines are provided for HBV prophylaxis and treatment of recurrence after
This document discusses liver transplantation for hepatitis C virus (HCV) disease. It outlines that HCV reinfection is common after transplantation, occurring in 87-97% of cases. There are different patterns of HCV recurrence post-transplant, including minimal liver injury, chronic HCV, and cholestatic HCV. Factors associated with increased rates of fibrosis post-transplant include older recipient age, bolus steroid use for rejection, induction with mycophenolic acid, and short duration of prednisone use. High pre-transplant HCV RNA levels are also associated with worse patient and graft survival outcomes.
- Liver resection (LR) and liver transplantation (LTx) are two treatment options for hepatocellular carcinoma (HCC). This study compares outcomes of 282 patients receiving LR and 187 receiving LTx.
- Patients who received LTx had a higher perioperative mortality rate compared to LR patients (18.1% vs 4.5%), mainly due to sepsis, multiple organ failure, and vascular complications. Late mortality was higher in LR patients and mainly due to tumor recurrence.
- Recurrence rates were significantly higher after LR (47.4% vs 9%), and survival after recurrence was also lower with LR. Factors associated with recurrence and survival included tumor characteristics such as α-fetoprotein levels,
1. Antiviral therapy both before and after liver transplantation is important to prevent recurrent infection of the graft by hepatitis B and C viruses.
2. Combination therapy with hepatitis B immune globulin and antiviral drugs like lamivudine is effective at preventing HBV recurrence in most patients.
3. Recurrence of HCV infection after transplantation is very common, but antiviral treatment with interferon or pegylated interferon plus ribavirin can achieve sustained virologic response in some patients and prevent progression of liver disease.
1. Mo rtality rate o n th e w aitin g
lis t fo r liv e r trans p lan tatio n
M.Vo ic u le s c u , Marian a Mih aila
C e n te r o f In te rn al Me d ic in e
Fu n d e n i C lin ic al In s titu te B u c h are s t
2. B ac kg ro u n d
- Liv e r tran s p lan tatio n is n o w re c o g n is e d as a
h ig h ly e ffe c tiv e fo rm o f tre atm e n t fo r p atie n ts w ith
e n d s tag e liv e r d is e as e .
- C u rre n tly , o n e an d fiv e y e ar s u rv iv al rate s are
in e x c e s s o f 8 0% .
- A s a c o n s e q u e n c e o f m an y d e v e lo p m e n ts in all
as p e c ts o f tran s p lan tatio n , in d ic atio n s h av e w id e n e d
an d c o n train d ic atio n s h av e b e c o m e fe w e r .
3. B ac kg ro u n d
- Th e in c re as e in th e n u m b e r o f p atie n ts re fe rre d
fo r tran s p lan tatio n h as n o t b e e n m atc h e d b y an
in c re as e in d o n o r rate s .
- Th e c o n s e q u e n c e o f th e re lativ e s h o rtag e o f
d o n o rs is :
- m o re p atie n ts are o n the w aitin g lis t fo r
tran s p lan tatio n
- th o s e o n th e w aitin g lis t b e c o m e s ic k e r b e fo re
th e y re c e iv e a g raft
- th e re is the lik e lih o o d o f m o re d e ath s o n
th e w aitin g lis t .
4. O b je c tiv e s
To u n d e rs tan d th e c au s e s o f d e ath an d als o to
id e n tify m arke rs w h ic h c o u ld d e te rm in e p atie n ts at
h ig h ris k o f d y in g o n th e w aitin g lis t, w e u n d e rto o k a
re tro s p e c tiv e an aly s is o f all p atie n ts (ad u lts an d
c h ild re n ) lis te d b e tw e e n J an u ary 2 0 0 1 an d De c e m b e r
2 0 0 2.
5. Mate rial and m e th o d (1 ) :
• This is a re tro s p e c tiv e s tu d y ;
• 10 9 p atie n ts w e re ac c e p te d fo r tran s p lan tatio n .
6. Mate rial and m e th o d (2 ) :
• A g e re p a rtit io n :
- ad u lts (>16 y e ars o ld ): m e an ag e 4 7 +/ .3 y e ars
-2
- c h ild re n (<16 y e ars o ld ): b e tw e e n 4 m o n th s an d
1 5 y e ars
• S e x re pa rt itio n :
- 41 fe m ale (37 .6 1 % )
- 66 m ale (62.3 9 % )
7. Mate rial and m e th o d (3 ) :
E tio lo g y o f C h ro nic Liv e r Dis e as e :
• c h ro n ic h e p atitis :
- HVB : 24 (22.01% )
- HB V+HDV : 15 (17.76% )
- HC V : 30 (27% )
- HB V+HC V : 8 ( 7. 33% )
• alc o h o lic liv e r d is e as e : 9 (8 .2 5 % )
• Wils o n ’s d is e as e : 8 (7 .3 4 % )
• o th e r 1 5 (1 3 .7 6 % ) :
- au to im m u n e h e p atitis
- p rim ary b iliary c irrho s is
- HHC
- m e tab o lic liv e r d is e as e
- b iliary atre s ia
8. Re s ults (1) :
- C h ild-P u g h s c o re a t a dm is s io n fo r a ll
g ro u ps :
- A =2 (1 .8 3 % )
- B =76 (6 9 .7 2 % )
- C =31 (2 8 .4 4 % )
- C h ild-P u g h s c o re a t a dm is s io n in
pa tie n ts
w h o die d:
- A =0
9. Re s ults (2) :
• Mo rta lity ra te :
- 16 p atie n ts in 2 4 m o n th s (9 .7 8 % / e ar)
y
• E tio lo g y o f c h ro n ic liv e r dis e a s e in
de c e a s e d pa tie n ts do e s n o t s e e m to
in flu e n c e the m o rta lity ra te :
- h e p atitis v iru s 1 0 (1 2 .9 8 % )
- alc o h o l 2 (22 .2 2 % )
- Wils o n ’s d is e as e 1 (1 2 ,5 % )
- o th e rs 3 (20% )
10. Re s ults (3) :
C a us es of death were the following:
- liv e r failu re 9 (5 6 .2 2 % )
- h e p ato re n al s y n d ro m e 4 (2 5 % )
- u p p e r d ig e s tiv e b le e d in g 3 (1 8 .7 8 % )
11. Dis c us s io ns :
- a ne w s c o re is us e d fo r im p ro v in g the m o rtality
rate in the liv e r tran s p lantatio n w aitin g lis t: the
ME LD s c o re (m o d e l fo r e nd s tag e liv e r d is e as e )
- th e ME LD s c o re is hig h ly p re d ic tiv e fo r
e v aluating th e ris k o f d e ath in p atie nts o n th e
w aiting lis t
ME LD s c o re = [0.957 x lo g e c r (m g / l) + 0.37 x lo g e b il
d
(m g / l) + 1.120 x lo g e (INR) + 0.643] x 10
d
12. Dis c us s io ns :
Waitin g lis t d ata fo r liv e r trans p lantatio n in th e UK
1990 1991 1992 1993 1994 1995 1996 1997
360 4439 504 577 629 675 872 696
N e w pts
re g is te re d
T ra n s pla n t s 358 421 508 534 620 669 640 671
Die d o n 37 30 42 57 51 56 59 66
a c tiv e lis t
R e m o v e d fro m 19 38 35 41 40 41 47 81
UKTS aA tiv e lis t
S c
13. Dis c us s io ns :
B lo o d T y pe Year
1995 1996 1997 1998 1999 2000 2001
T o ta l P a tie n t s 10475 12734 14947 17807 21063 23561 25746
De a t h s 829 998 1187 1421 1821 1763 1978
Ra te 1 7 7 ,4 1 5 6 ,4 1 4 3 ,8 1 3 7 ,0 1 4 1 ,9 1 1 7 ,2 1 1 4 ,7
O P a tie n t s 5083 6226 7340 8782 10358 11572 12598
De a t h s 437 513 621 751 915 919 1 ,0 1 4
Ra te 1 8 0 ,6 1 5 3 ,3 1 4 6 ,0 1 4 0 ,8 1 3 9 ,6 1 1 9 ,8 1 1 6 ,6
A P a tie n t s 3744 4635 5366 6370 7549 8533 9273
De a t h s 254 336 384 488 645 589 661
Ra te 1 6 2 ,4 1 5 4 ,5 1 3 3 ,2 1 3 5 ,4 1 4 4 ,5 1 1 1 ,7 1 1 1 ,8
B P a tie n t s 1272 1423 1702 2066 2473 2735 3047
De a t h s 111 116 143 139 208 199 228
Ra te 2 0 2 ,0 1 7 4 ,1 1 6 2 ,3 1 2 1 ,7 1 4 3 ,3 1 1 8 ,0 1 1 5 ,8
14. Dis c us s io ns :
Re p o rte d d e ath s an d an n u al d e ath rate s p e r 1 00 0 p atie n t y e ars
G e n de r Year
1995 1996 1997 1998 1999 2000 2001
T o ta l P a t ie n t s 10475 12734 14947 17807 21063 23561 25746
De a t hs 829 998 1187 1421 1821 1763 1978
Ra te 1 7 7 ,4 1 5 6 ,4 1 4 3 ,8 1 3 7 ,0 1 4 1 ,9 1 1 7 ,2 1 1 4 ,7
F e m a le P a t ie n t s 4728 5584 6440 7498 8827 9830 10686
De a t hs 356 420 486 601 742 701 830
Ra te 1 6 3 ,2 1 4 5 ,4 1 3 4 ,0 1 3 4 ,2 1 3 5 ,1 1 0 9 ,2 1 1 3 ,1
Ma le
O PTN/ RTR
S P a t ie n t s 5747 7150 8507 10309 12236 13731 15060
16. C o n c lus io ns (1) :
- th e annu al m o rtality rate (9.78% ) is s im ilar
to d ata fro m the lite rature (5-12% )
17. C o n c lus io ns (1) :
- th e m o rtality rate is NO T in flu e n c e d b y
e tio lo g y o f c h ro n ic liv e r d is e as e
- th e m o rtality rate is in flu e n c e d b y th e s e v e rity
o f th e d is e as e at ad m is s io n to th e w aitin g lis t
18. C o n c lus io ns (2) :
- th e m ain c au s e s o f d e ath are re p re s e n te d b y
liv e r failu re , fo llo w e d b y h e p ato -re n al s y n d ro m e an d
u p p e r d ig e s tiv e b le e d in g
- im p ro v e m e n t o f th e m o rtality rate c o u ld b e
o b tain e d th ro u g h a b e tte r c o n tro l o f th e c au s e s o f
d e ath , b e c au s e th e n u m b e r o f d o n o rs c an n o t b e
in flu e n c e d
- th e p re c o c io u s d iag n o s is o f h e p ato -re n al
s y n d ro m e an d p re v e n tio n o f u p p e r d ig e s tiv e b le e d in g
m ay b e th e o n ly m e as u re s th at c an b e tak e n fo r
re d u c in g m o rtality , b e c au s e liv e r failu re c an n o t b e
p re v e n te d b y m e d ic al m e as u re s
19. C o n c lus io ns (3) :
- d e s p ite th e in n o v ativ e u s e o f te c h n iq u e s to
m ake fu lle s t u s e o f th e d o n o r p o o l, s u c h as s p littin g
o f liv e rs an d in c re as in g u s e o f m arg in al liv e rs (th o s e
liv e rs w h e re th e re is d o u b t as to in itial g raft fu n c tio n ),
th e d e m an d fo r tran s p lan tatio n is failin g to m e e t th e
s u p p ly
- m o rtality o n th e w aitin g lis t is a s ig n ific an t
p ro b le m an d is like ly to ris e fu rth e r u n til d o n o r
s h o rtag e c an b e re v e rs e d o r alte rn ativ e s trate g ie s c an
b e in tro d u c e d
- tim in g o f re fe rral fo r c o n s id e ratio n o f
tran s p lan tatio n re m ain s p ro b le m atic
20. C o n c lus io ns (4) :
- if p atie n ts are re fe rre d an d lis te d e arly fo r
tran s p lan tatio n th e n , b e c au s e o f th e p e rio p e rativ e
ris k an d s m all e arly m o rtality , th e re is a ris k th e
p atie n t’s life m ig h t b e s h o rte n e d
- th e tran s p lan t c lin ic ian s n e e d to e s tab lis h
g u id e lin e s to d e te rm in e w h e n th e p atie n t’s c h an c e s
o f s u rv iv al are s o lo w th at tran s p lan tatio n b e c o m e s
n o lo n g e r in d ic ate d